GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Research & Development

NewAmsterdam Pharma Co NV (FRA:KH6) Research & Development : €146.67 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. NewAmsterdam Pharma Co NV's Research & Development for the six months ended in Dec. 2023 was €73.57 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was €146.67 Mil.


NewAmsterdam Pharma Co NV Research & Development Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Research & Development Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Research & Development
4.09 25.64 81.89 146.19

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial 16.63 30.23 51.72 73.10 73.57

NewAmsterdam Pharma Co NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €146.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NewAmsterdam Pharma Co NV  (FRA:KH6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


NewAmsterdam Pharma Co NV Research & Development Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines